Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.38 |
| ▸ | HTR2B | P41595 | 6/20 | 0.35 |
| ▸ | HTR7 | P34969 | 5/20 | 0.35 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.34 |
| ▸ | MKNK2 | Q9HBH9 | 1/20 | 0.34 |
| ▸ | CHEK2 | O96017 | 1/20 | 0.33 |
| ▸ | SLC9A1 | P19634 | 2/20 | 0.33 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.33 |
| ▸ | GCK | P35557 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.33 |
| ▸ | CDK2 | P24941 | 1/20 | 0.33 |
| ▸ | GSK3B | P49841 | 1/20 | 0.33 |
| ▸ | HTR5A | P47898 | 2/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12366604 | 0.84 | HTR5A (0.41) | HTR2BHTR7HTR5A | |
| SCHEMBL12366593 | 0.79 | MKNK1 (0.42) | HTR2BHTR7MKNK1MKNK2CHEK2 | |
| SCHEMBL12366547 | 0.79 | SLC9A1 (0.41) | HTR2BHTR7SLC9A1HTR5A | |
| SCHEMBL12366598 | 0.79 | HTR2B (0.40) | HTR2BHTR7SLC9A1 | |
| SCHEMBL12366374 | 0.78 | HTR2B (0.47) | HTR2BHTR7SLC9A1 | |
| SCHEMBL12366611 | 0.77 | HTR2B (0.39) | HTR2BHTR7SLC9A1HTR5A | |
| SCHEMBL12366635 | 0.76 | HTR5A (0.49) | HTR2BHTR7HTR5A | |
| SCHEMBL12366492 | 0.76 | SLC9A1 (0.39) | HTR2BHTR7SLC9A1 | |
| SCHEMBL12366644 | 0.75 | HTR2B (0.39) | HTR2BHTR7CHEK2SLC9A1 | |
| SCHEMBL12366615 | 0.75 | HTR5A (0.40) | HTR2BHTR7HTR5A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110207729-A1 | BICYCLIC ACYLGUANIDINE DERIVATIVE | ASTELLAS PHARMA INC. (JP) | 2011-08-25 | — | — | US | disclosed |
| US-20110207729-A1 | BICYCLIC ACYLGUANIDINE DERIVATIVE | ASTELLAS PHARMA INC. (JP) | 2011-08-25 | — | — | US | disclosed |
| EP-2177505-A1 | BICYCLIC ACYLGUANIDINE DERIVATIVE | Astellas Pharma Inc. (JP) | 2010-04-21 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110207729-A1 | BICYCLIC ACYLGUANIDINE DERIVATIVE | HTR5A, HTR2A, HTR1E | MAPT 463/4885HTR2B 7/4885HTR7 13/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.